BNP Paribas Financial Markets Has $27,000 Stock Position in InfuSystem Holdings, Inc. (NYSE:INFU)

BNP Paribas Financial Markets grew its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 66.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,076 shares of the company’s stock after buying an additional 1,626 shares during the quarter. BNP Paribas Financial Markets’ holdings in InfuSystem were worth $27,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of INFU. Oppenheimer Asset Management Inc. raised its holdings in InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock valued at $223,000 after buying an additional 7,295 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of InfuSystem by 23.9% during the third quarter. GSA Capital Partners LLP now owns 65,680 shares of the company’s stock worth $440,000 after purchasing an additional 12,657 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of InfuSystem by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after purchasing an additional 5,391 shares during the period. Panagora Asset Management Inc. acquired a new position in InfuSystem during the 2nd quarter worth about $208,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of InfuSystem in the 3rd quarter valued at about $87,000. 71.13% of the stock is currently owned by institutional investors and hedge funds.

InfuSystem Trading Up 4.4 %

Shares of InfuSystem stock opened at $8.31 on Friday. The company has a market capitalization of $176.70 million, a price-to-earnings ratio of 138.52 and a beta of 1.53. The stock’s fifty day simple moving average is $8.05. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12 month low of $5.74 and a 12 month high of $10.89.

Insider Transactions at InfuSystem

In related news, CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $8.87, for a total value of $47,880.26. Following the sale, the chief executive officer now directly owns 416,659 shares in the company, valued at approximately $3,695,765.33. The trade was a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th. B. Riley started coverage on shares of InfuSystem in a report on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective for the company.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.